ABAntoon Billiet

Antoon Billiet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antoon Billiet has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world feasibility and safety of neoadjuvant FOLFIRINOX in pancreatic ductal adenocarcinoma: a retrospective single-center study

    by Soetkin D’HAens, Antoon Billiet, Halit Topal, Baki Topal, Filip Van Herpe, Jeroen Dekervel

    Background: Neoadjuvant chemotherapy in non-metastatic pancreatic ductal adenocarcinoma (PDAC) is increasingly being studied and used in clinical practice. However, this strategy is associated with significant toxicity, biopsy-related and biliary complications and possible treatment delay. We aimed to assess the feasible number of cycles of neoadjuvant (modified) FOLFIRINOX and the real-world toxicity, to inform an optimal interventional trial design. Methods: In this descriptive monocentric study, we identified patients with borderline resectable or locally advanced PDAC, treated with upfront (m)FOLFIRINOX from 2020 to 2023. We analyzed patient and disease characteristics, dosing of therapy, occurrence of serious adverse events (SAEs) and reasons for discontinuation, and compared this data with available evidence in the literature. Results: Eighty-one patients were included. Median age was 65, most patients had an ECOG performance status of 0. 62.5% of tumors were borderline resectable, the others were locally advanced. 49 patients (60.5%) received mFOLFIRINOX, 32 (39.5%) received FOLFIRINOX and the median number of cycles administered was six. Most common reasons for discontinuation were surgery (n=45, 55.6%) and persistently inoperable or progressive disease (n=25, 30.9%), with toxicity accounting for a much smaller proportion (n=5, 6.2%). Global dose intensities gradually decreased over time. Dose reduction was necessary in 43 patients (53%), and 37 patients (45.7%) needed inpatient care. However, supportive care measures allowed most patients to overcome toxicity and finish the planned treatment cycles. Conclusions: With adequate supportive care and dose modifications, the majority of patients were able to complete the assigned chemotherapy cycles. Eight cycles of mFOLFIRINOX appear feasible for most patients and may serve as an optimal regimen for evaluation in future interventional trials.

  • Open Access

    Questionnaire PLD‐complaint‐specific assessment identifies need for therapy in polycystic liver disease: A multi‐centric prospective study

    by Antoon Billiet, Frederik Temmerman, Walter Coudyzer, Natalie Van Den Ende, Isabelle Colle, Sven Francque, Stephane De Maeght, Filip Janssens, Hans Orlent, Dirk Sprengers, et al.

    Background and AimsPolycystic liver disease (PLD) can lead to extensive hepatomegaly. Symptom relief is the primary goal of the treatment. The role of the recently developed disease-specific questionnaires for identification of the thresholds and the assessment of therapy needs further investigation. MethodsA five-year prospective multi-centric observational study in 21 hospitals in Belgium gathered a study population of 198 symptomatic PLD-patients of whom the disease-specific symptom questionnaire PLD-complaint-specific assessment (POLCA) scores were calculated. The thresholds of the POLCA score for the need for volume reduction therapy were analyzed. ResultsThe study group consisted of mostly (82.8%) women with baseline mean age of 54.4 years +/- 11.2, median liver volume expressed as height-adjusted total liver volume(htLV) of 1994 mL (interquartile range [IQR] 1275; 3150) and median growth of the liver of +74 mL/year (IQR +3; +230). Volume reduction therapy was needed in 71 patients (35.9%). A POLCA severity score (SPI) >= 14 predicted the need for therapy both in the derivation (n = 63) and the validation cohort (n = 126). The thresholds to start somatostatin analogues (n = 55) or to consider liver transplantation (n = 18) were SPI scores of >= 14 and >= 18 and the corresponding mean htLVs were 2902 mL (IQR 1908; 3964) and 3607 mL (IQR 2901; 4337), respectively. Somatostatin analogues treatment resulted in a decrease in the SPI score -6.0 versus + 4.5 in patients without somatostatin analogues (p < 0.01). Changes in the SPI score were significantly different between the liver transplantation group and no liver transplantation group, +4.3 +/- 7.1 versus -1.6 +/- 4.9, respectively, (p < 0.01). ConclusionA polycystic liver disease-specific questionnaire can be used as a guide on when to start a volume reduction therapy and to assess the effect of treatment.


  • A yellow sign indicating danger ahead

    by A Billiet, K Moubax, L Libbrecht, W Van Moerkercke